A First-in-Human, phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of CB-03 in healthy subjects
Latest Information Update: 18 May 2022
At a glance
- Drugs CB 03 (Primary)
- Indications Epilepsy
- Focus Adverse reactions; First in man
- Sponsors Zhimeng Biopharma
Most Recent Events
- 18 May 2022 New trial record
- 11 May 2022 According to a Zhimeng Biopharma media release, first subject has been dosed in this study .